Alkermes plc. (ALKS) · Nov 3, 2026 · Earnings

Alkermes earnings beat as LUMRYZ growth offsets weaker royalty revenue

Beat — Q3 revenue $480.1M vs ~$463.5M consensus

Alkermes earnings beat Q3 revenue expectations on LUMRYZ and core-product growth, while adjusted EBITDA slipped and full-year guidance stayed unchanged.

Alkermes is in the middle of a commercial expansion: it added Avadel’s LUMRYZ to its neuroscience portfolio in February 2026 and is using the product to diversify beyond its established VIVITROL, ARISTADA, and LYBALVI franchises. The quarter advances that strategy, but does not materially change the broader outlook. The acquisition and LUMRYZ ramp were already known; the new information is the pace of contribution relative to expectations. Published Q3 revenue consensus was about $463.5 million.

Revenue cleared expectations, led by the newly acquired product. Total revenue was $480.1 million, roughly 3.6% above the published consensus, with proprietary net sales up sharply year over year. LUMRYZ contributed $89.9 million in its first full post-acquisition quarter, while VIVITROL and ARISTADA also grew; that combination more than offset the decline in manufacturing and royalty revenue.

Q3 2026Q3 2025Consensus
Total revenue (Revenue Summary)$480.1M (+21.8%)$394.2M~$463.5M
Proprietary net sales (Revenue Summary)$417.3M (+31.5%)$317.4M
VIVITROL net sales (Revenue Summary)$127.6M (+5.4%)$121.1M
ARISTADA net sales (Revenue Summary)$103.9M (+5.9%)$98.1M
LYBALVI net sales (Revenue Summary)$95.9M (-2.3%)$98.2M
LUMRYZ net sales (Revenue Summary)$89.9M—
Manufacturing & royalty revenue (Revenue Summary)$62.9M (-18.1%)$76.8M
Adjusted EBITDA (GAAP to Non-GAAP Reconciliation)$120.1M (-1.2%)$121.5M

The quality of the beat is mixed rather than broad-based. LUMRYZ is scaling, with approximately 4,100 patients on therapy as of September 30, but LYBALVI sales declined and gross-to-net deductions were already about 42%, with the company expecting roughly 45% in 2027. That suggests the revenue beat is being supported by a product ramp while pricing and access pressure remain an issue for LYBALVI. 〔0〕 〔1〕

Profitability did not improve with the revenue beat. Adjusted EBITDA was $120.1 million versus $121.5 million a year earlier, reflecting the cost burden of the Avadel integration and LUMRYZ-related acquisition accounting. The filing’s GAAP reconciliation shows $29.8 million of acquisition-related costs in the quarter, so the reported earnings profile remains noisy even as the commercial portfolio expands. 〔2〕

Management left the full-year framework unchanged. The company reiterated 2026 revenue of $1.73 billion to $1.84 billion and adjusted EBITDA of $370 million to $410 million rather than raising the outlook after the revenue beat. 〔3〕

Bottom line: This is a modest earnings beat that validates the LUMRYZ-led expansion, but unchanged guidance and softer underlying profitability keep it from rewriting the Alkermes story. The business is progressing, though more of the growth is now dependent on successfully scaling the acquired sleep-medicine product.

Original filing on SEC EDGAR

More Alkermes plc. news

Alkermes earnings beat as LUMRYZ growth offsets weaker royalty revenue | ALKS Stock News
AllSight

Breaking down Wall Street's
information edge.

A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.

—
8-K events this week
—
filings analyzed in total
live · updated 30s ago
Live events · whole market · · --:--:-- ET
AllSight read
Straight from the 8-K
Verbatim from the filing AllSight decoded — highlighted above. Open on SEC EDGAR ↗
Limited-time offerFree 14-day Pro trial
AllSight

Sign in to AllSight

  • Follow any company — we email you the moment it files, free!
  • Your watchlist saved to your account, on every device — free!

by Signing in NOW, claim your FREE 14-day Pro trial!

No password. We email you a 6-digit code. By continuing you agree to our Terms & Privacy.
AllSight · Live plain-English 8-K decodes across the whole US market · Not investment advice.